IL1B and macrophage activation syndrome: Importantly, the EULAR/ACR/PRINTO 2016 classification criteria26 remain accurate and applicable to aid in the diagnosis of MAS in patients with sJIA‐SD receiving IL‐1 pathway–targeted treatment (either anakinra or canakinumab).